Mylan Inc.

🇺🇸United States
Ownership
-
Established
1961-01-01
Employees
35K
Market Cap
-
Website
https://www.mylan.com/

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

First Posted Date
2015-05-20
Last Posted Date
2022-03-22
Lead Sponsor
Mylan Inc.
Target Recruit Count
409
Registration Number
NCT02449031
Locations
🇺🇸

Novartis Investigative Site, Spokane, Washington, United States

Comparison of Efficacy on Healing, and Safety of Two Dressings Urgotul and TulleGras MS on Surgical Acute Wounds.

Not Applicable
Completed
Conditions
First Posted Date
2014-12-23
Last Posted Date
2022-03-21
Lead Sponsor
Mylan Inc.
Target Recruit Count
208
Registration Number
NCT02322710
Locations
🇫🇷

Research facility ID ORG-001264, Ajaccio, France

🇫🇷

Research facility ID ORG-001263, Angoulême, France

🇫🇷

Research facility ORG-001090, Athis-Mons, France

and more 30 locations

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

First Posted Date
2014-08-28
Last Posted Date
2022-03-03
Lead Sponsor
Mylan Inc.
Target Recruit Count
560
Registration Number
NCT02227875
Locations
🇨🇳

Mylan Investigational Site, Taipei, Taiwan

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

First Posted Date
2014-08-28
Last Posted Date
2022-03-03
Lead Sponsor
Mylan Inc.
Target Recruit Count
558
Registration Number
NCT02227862
Locations
🇺🇸

Texas Diabetes & Endocrinology, Round Rock, Texas, United States

🇬🇧

Mylan Investigational Site, Swansea, United Kingdom

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2014-04-09
Last Posted Date
2022-02-24
Lead Sponsor
Mylan Inc.
Target Recruit Count
64
Registration Number
NCT02109172
Locations
🇺🇸

American Health Research, Charlotte, North Carolina, United States

Evaluation of Pain Associated With the Removal of Wound Dressing During Care of Venous Leg Ulcer. Comparison of the Efficacy and Safety of Two Dressings Urgotul and TulleGras

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2014-04-04
Last Posted Date
2022-03-21
Lead Sponsor
Mylan Inc.
Target Recruit Count
62
Registration Number
NCT02104180
Locations
🇫🇷

Research facility ID ORG-000845, Tarare, France

🇫🇷

Research Facility ID ORG-001183, Angoulème, France

🇫🇷

Research Facility ID ORG-000857, Annecy, France

and more 24 locations

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

First Posted Date
2014-03-24
Last Posted Date
2023-04-26
Lead Sponsor
Mylan Inc.
Target Recruit Count
130
Registration Number
NCT02094716
Locations
🇵🇷

Clinical Research Site, Ponce, Puerto Rico

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-01-20
Last Posted Date
2022-02-24
Lead Sponsor
Mylan Inc.
Target Recruit Count
355
Registration Number
NCT02040792
Locations
🇺🇸

Upstate Pharmaceutical Research, Greenville, South Carolina, United States

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-10-11
Last Posted Date
2022-02-24
Lead Sponsor
Mylan Inc.
Target Recruit Count
62
Registration Number
NCT01704404
Locations
🇳🇿

P3 Research Ltd, Wellington, New Zealand

Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study

Completed
Conditions
First Posted Date
2012-07-03
Last Posted Date
2022-03-31
Lead Sponsor
Mylan Inc.
Target Recruit Count
1531
Registration Number
NCT01632878
Locations
🇧🇬

Site Reference ID/Investigator# 81558, Plovdiv, Bulgaria

© Copyright 2024. All Rights Reserved by MedPath